- Home
- WRN vs NBTX Comparison
WRN vs NBTX Comparison
Compare WRN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- NBTX
- Stock Information
- Founded
- WRN 2006
- NBTX 2003
- Country
- WRN Canada
- NBTX France
- Employees
- WRN N/A
- NBTX N/A
- Industry
- WRN Metal Mining
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- NBTX Health Care
- Exchange
- WRN Nasdaq
- NBTX Nasdaq
- Market Cap
- WRN 237.4M
- NBTX 201.9M
- IPO Year
- WRN N/A
- NBTX 2020
- Fundamental
- Price
- WRN $1.14
- NBTX $3.79
- Analyst Decision
- WRN Strong Buy
- NBTX Strong Buy
- Analyst Count
- WRN 1
- NBTX 2
- Target Price
- WRN $4.25
- NBTX $11.50
- AVG Volume (30 Days)
- WRN 461.7K
- NBTX 8.0K
- Earning Date
- WRN 11-07-2024
- NBTX 12-03-2024
- Dividend Yield
- WRN N/A
- NBTX N/A
- EPS Growth
- WRN N/A
- NBTX N/A
- EPS
- WRN N/A
- NBTX N/A
- Revenue
- WRN N/A
- NBTX $45,220,186.00
- Revenue This Year
- WRN N/A
- NBTX N/A
- Revenue Next Year
- WRN N/A
- NBTX N/A
- P/E Ratio
- WRN N/A
- NBTX N/A
- Revenue Growth
- WRN N/A
- NBTX 526.17
- 52 Week Low
- WRN $0.95
- NBTX $3.57
- 52 Week High
- WRN $1.66
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- WRN 45.00
- NBTX 37.88
- Support Level
- WRN $1.11
- NBTX $3.57
- Resistance Level
- WRN $1.16
- NBTX $4.11
- Average True Range (ATR)
- WRN 0.06
- NBTX 0.28
- MACD
- WRN -0.00
- NBTX -0.00
- Stochastic Oscillator
- WRN 23.91
- NBTX 22.05
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.